What Eucol Treats: Main Uses and Benefits

The therapeutic application of Eucol (Paclitaxel) is confined to the systemic management of malignant neoplasms (cancer), targeting the uncontrolled growth of specific solid tumors and associated disease progression. The primary benefit provided is measurable disease control and supports the management of disease progression.

The active substance, paclitaxel, is used in the therapeutic area of specific cancers in adults. It is commonly used to help manage advanced-stage breast cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and AIDS-related Kaposi's sarcoma.

Eucol is applied in critical clinical settings involving advanced-stage malignancy or the goal of reducing the risk of disease recurrence in the adjuvant setting. This addresses the profound symptomatic manifestations associated with widespread cancer (metastatic disease) or the high risk of relapse after initial therapy. As part of managing the disease, the treatment offers supportive therapeutic relief that helps patients cope more steadily with difficult episodes.

“This therapy supports the stabilization of disease progression and assists with maintaining functional stability when symptoms create noticeable interference with daily functioning.”

Quick Fact: Relief for Systemic Discomfort

Regulatory References

1. European Medicines Agency's product information for Abraxane

Eucol is restricted to adult patients (ge 18 years) who meet specific physiological criteria documented in official regulatory labeling. Use is not recommended for children and adolescents because safety and efficacy have not been established in the pediatric population.

Populations Who Must Not Use Eucol (Contraindications)

Use of the medicine is strictly contraindicated in several specific populations:

• Patients with a confirmed severe hypersensitivity reaction to the active substance (Paclitaxel) or to the excipient polyoxyethylated castor oil.
• Patients with solid tumors who have a baseline neutrophil count less than 1,500 cells/mm^3 (or less than 1,000 cells/mm^3 for AIDS-related Kaposi's sarcoma).
• Individuals who are breastfeeding (lactation).
• Patients presenting with severe hepatic impairment.

Eligibility-Related Restrictions

The medicine is generally not recommended for use during pregnancy due to the potential for fetal harm. Women of childbearing potential and male patients of fertile age must use effective contraception during and for a period after treatment. Additionally, data are officially insufficient to recommend use in patients with severe renal impairment.

Interactions with other medicines and products

Official regulatory documents define Eucol's interaction profile based on pharmacokinetic and procedural constraints.

Pharmacokinetic Interactions

Eucol (Paclitaxel) is primarily metabolized by the Cytochrome P450 isoenzyme CYP2C8 and, to a lesser extent, by CYP3A4. Consequently, co-administration with other medicinal products classified as strong inhibitors or inducers of these enzymes may formally alter the plasma exposure of Eucol. In vitro data has noted inhibition of Eucol metabolism by specific agents, including ketoconazole, quinidine, and cyclosporin, which may impact the drug's clearance.

Administration Timing Constraints

When Eucol is administered in combination regimens, specific timing rules apply. Eucol must be administered before Cisplatin when these two agents are combined. Conversely, Eucol must be administered 24 hours after Doxorubicin to comply with established regulatory protocols.

Other Official Restrictions

• Formulation Excipient: Eucol is contraindicated in patients with a history of severe hypersensitivity to the excipient Polyoxyl 35 Castor Oil (also known as Cremophor EL).
• Population Constraint: Patients with hepatic impairment are noted in official labeling to have an increased risk of toxicity from interactions due to potential alterations in drug exposure.

Targeting the Histamine Signaling Pathway

Eucol's primary mechanism involves acting as a selective antagonist at the histamine H1 receptor. The drug binds to this receptor site, thereby preventing the natural signaling molecule, histamine, from initiating its characteristic cascade of cellular events. This interaction effectively suppresses the receptor's activation and alters the subsequent signaling sequence that follows receptor engagement.

Modulating Microvascular Permeability

This specific antagonism influences the microvascular system by interfering with the histamine-driven cascade that typically causes small blood vessels (capillaries) to relax and increase permeability. The action restricts the extent of mediator activity and maintains the integrity of the vessel walls, resulting in a reduction in fluid translocation from the circulation. Eucol's mechanism influences signal transduction primarily in the periphery, exhibiting limited penetration of the central nervous system.

How to Use Eucol

Eucol (Paclitaxel) is administered according to established protocols that govern the route, preparation, and timing of each treatment course. As a concentrate, the medicine is exclusively administered via Intravenous (IV) Infusion by a healthcare professional, typically in a clinical setting, to ensure controlled delivery.

---

Administration Requirements

Category	Instructions
Route of Administration	Intravenous (IV) Infusion only.
Standard Dose Range	Regimens typically use doses such as 175 mg/m^2 (3-hour infusion) or 135 mg/m^2 (24-hour infusion), depending on the specific combination and indication.
Frequency & Timing	The most common schedule is an every three-week (q3 W) cycle, though an every two-week schedule is prescribed for certain uses (e.g., AIDS-related Kaposi's Sarcoma).

---

Preparation and Conditions of Use

Prior to every infusion, patients must receive mandatory premedication (corticosteroids and antihistamines). The Eucol concentrate must be diluted in appropriate solutions (such as 0.9% Sodium Chloride or 5% Dextrose) to a final concentration between 0.3 and 1.2 mg/mL.

For administration, the prepared solution must be infused through non-PVC equipment using a 0.22 micron in-line filter. When Eucol is part of a combination regimen with a platinum-based drug, it must be administered before the platinum agent to follow the required sequence.

Treatment courses are conditional on patient status: the start of a new cycle is restricted until the patient's absolute neutrophil count (ANC) is at least 1500 cells/mm^3 and the platelet count is at least 100,000 cells/mm^3.

Research Evidence / Overview of Studies for Eucol (Paclitaxel)

Evidence for Use in Advanced Breast Cancer

The clinical research for Eucol (Paclitaxel) in advanced breast cancer includes large-scale Randomized Controlled Trials (RCTs) and Systematic Reviews that compare different treatment approaches. These studies were conducted to explore how symptoms change over time and to track key outcomes related to disease management (as defined by the study endpoints). The trials observed adult women with either recurrent or metastatic breast carcinoma, including those who had previously received chemotherapy.

What the studies reported: Studies monitored several crucial outcomes, including Overall Survival (OS) and Progression-Free Survival (PFS). Studies monitored patterns related to tumor size changes and recorded the Overall Response Rate in the observed populations. Research explored the relationship between different administration schedules, such as weekly versus less frequent dosing, and the measured outcomes.

Evidence in the Adjuvant (Post-Surgery) Setting

For patients with node-positive breast cancer, research has focused on the use of Eucol following initial therapy. The evidence primarily comes from large-scale cooperative group RCTs with long-term follow-up. These studies explored long-term, event-based measures of long-term event prevention (such as recurrence). Studies monitored Disease-Free Survival (DFS) and Overall Survival (OS) to capture phases of heightened symptom activity. Research monitored patterns related to recurrence events and assessed the risk in these specific, closely monitored populations.

---

Evidence for Use in Advanced Ovarian Carcinoma

The foundational research for Eucol in advanced ovarian carcinoma comes from Multicenter Phase 3 Randomized Controlled Trials. These studies were conducted to evaluate Eucol, typically in combination with a platinum agent, as a first-line approach. Researchers monitored long-term measures of disease management (as defined by the study endpoints), including Overall Survival (OS) and Progression-Free Survival (PFS), and evaluated patient-reported outcomes describing perceived discomfort. Research provided data related to long-term patient survival observed in the specific trial cohorts.

---

What is Still Uncertain About Eucol's Evidence

Scientific literature and regulatory reviews acknowledge several limitations and areas for ongoing research. For example, evidence quality varies across studies, and long-term effects are not fully established when comparing Eucol against newer drug classes. Researchers continue to explore the optimal way to use Eucol, including assessing which specific administration schedules provide the most observed patterns of stability. Additionally, comparative evidence is lacking when assessing Eucol against some of the newest treatment standards, and subgroup findings are uncertain for certain rare patient characteristics.

Key Studies & References

1. Paclitaxel in Breast Cancer: Review of Phase III Randomized Trials (Adjuvant and Metastatic Settings)
2. First-line Nab-paclitaxel Shows Efficacy in NSCLC Trials (Review of Phase II/III Trials for NSCLC)

Common questions about Eucol (FAQ)

Q: Does Eucol have an established generic version available?

A: Eucol is a brand name for the active ingredient, which is known by its International Nonproprietary Name (INN) as Paclitaxel. According to official sources, Paclitaxel is widely available in generic forms, which are generally equivalent to the brand name product.

Q: Is it normal to feel mild nausea when first starting Eucol?

A: Nausea is classified in the official prescribing information as a Very Common side effect, meaning it affects more than 1 in 10 patients. It is listed among the most frequently reported gastrointestinal side effects associated with the treatment.

Q: Are there any known food or beverage interactions listed for Eucol (e.g., grapefruit)?

A: Yes, official regulatory information specifically notes that grapefruits and grapefruit juice may increase the amount of Eucol in the bloodstream. This is related to how the medicine is metabolized by enzymes in the body, which can be affected by these foods.

Q: Does Eucol interact with common over-the-counter pain relievers like ibuprofen or acetaminophen?

A: Eucol is metabolized (broken down) by specific enzymes in the liver. Official drug interaction data indicates that substances like acetaminophen (a common pain reliever) can potentially alter how quickly Eucol is metabolized. Information regarding all co-administered medicines is important for a healthcare provider to review.

Q: What have clinical studies shown regarding the long-term outcomes of using Eucol?

A: Clinical research has examined long-term patient outcomes to assess the patterns related to disease management over time. Studies tracked key long-term metrics, including Overall Survival (OS) and Disease-Free Survival (DFS), for patients treated with Eucol.

Q: How does the action of Eucol compare to a placebo in clinical trials?

A: The foundational research for Eucol involved Randomized Controlled Trials (RCTs), where the drug’s performance was measured against a control group (such as a placebo or standard treatment). These studies were conducted to determine the drug's effect on key outcomes like Disease-Free Survival (DFS) and Overall Survival (OS).

Q: Is Eucol commonly described as causing drowsiness?

A: Official summaries of reported adverse reactions list drowsiness as a common side effect for some patients. This is typically categorized under Nervous System disorders in the official labeling.

Q: Are there warnings about Eucol impacting a person's ability to drive?

A: Yes, official warnings note that side effects such as dizziness and drowsiness could potentially impair a person's ability to drive or operate machinery. This warning is based on the risk associated with these specific adverse reactions.

Q: Does Eucol have a known association with weight gain or weight loss?

A: Official documentation for Eucol lists unusual weight gain or loss as a less common side effect. Although not a 'Very Common' occurrence, this change is included in the reported adverse reactions.

Q: What is the difference between the brand name and the generic name for Eucol?

A: The brand name for the medicine is Eucol, which is the proprietary name used by the manufacturer. The name of the active chemical ingredient is Paclitaxel, which is the generic name (or INN) used globally.

Q: Is Eucol primarily used to manage symptoms or address the underlying cause of the condition?

A: Eucol is classified as a potent cytotoxic antineoplastic drug that functions as a mitotic inhibitor. This mechanism of action is designed to disrupt the rapid, abnormal growth of malignant cells.

Q: What are the known food or beverage interactions listed for Eucol?

A: Official regulatory information specifically notes that grapefruits and grapefruit juice may affect the body’s metabolism of the drug. This is related to how the medicine is metabolized by enzymes in the body, which can be affected by these foods.

Q: Can Eucol be taken with common dietary supplements or vitamins?

A: Regulatory documents note caution regarding co-administration with any product—including supplements and vitamins—classified as a strong inhibitor or inducer of the CYP2C8 and CYP3A4 enzymes. These products may formally alter the concentration of Eucol in the blood.

Q: Is Eucol generally suitable for use in pediatric patients (children)?

A: According to official regulatory labeling, the use of Eucol is not recommended for children and adolescents (patients under 18 years old). This is because the safety and effectiveness of the drug have not been definitively established in the pediatric population.

Q: Are there any existing health conditions that officially preclude the use of Eucol?

A: Yes, official labeling includes restrictions for specific populations. Contraindications include known severe hypersensitivity to the drug's components, severe hepatic impairment, and having a low baseline neutrophil count. Official documentation notes that certain pre-existing conditions, such as specific types of peripheral neuropathy or heart rhythm problems, may also require caution.

Q: Is there an interaction listed between Eucol and St. John’s Wort?

A: While the regulatory labeling may not explicitly name St. John’s Wort, it warns against using substances that are strong inducers of the CYP2C8 and CYP3A4 enzymes. Regulatory documents note caution regarding co-administration with such products, as St. John's Wort is commonly recognized as a strong inducer.

Q: Are there ongoing studies exploring new uses for Eucol?

A: Scientific literature and regulatory reviews acknowledge that Eucol remains an active area for investigation. Areas of ongoing research include determining the optimal administration schedules and gathering additional comparative evidence against newer treatment classes.

Q: What is the common reason for patients to discontinue Eucol in clinical settings?

A: In clinical settings, treatment may be interrupted, delayed, or stopped based on patient tolerance and the severity of side effects. Common factors leading to discontinuation or delay include the development of severe side effects, like serious peripheral neuropathy, or when blood cell counts fall below the minimum mandated levels.

Q: Are there any routine monitoring tests (like blood work) suggested for patients taking Eucol?

A: Yes, official requirements mandate that patients undergo frequent peripheral blood cell counts during treatment. Specifically, neutrophil and platelet counts must be checked to monitor for bone marrow suppression before the start of each new treatment cycle.

Q: Does Eucol affect or interact with any routine laboratory test results?

A: Yes. Due to its intended action, Eucol can significantly lower a patient’s white blood cell counts and platelet counts, which will be reflected in laboratory tests. Changes in liver function tests have also been reported in clinical data.

Q: Are there any major organs (liver, kidney) that Eucol is known to affect?

A: Official documentation notes effects on the Blood and Lymphatic System (myelosuppression) and the Nervous System (peripheral neuropathy). The labeling also contains warnings regarding the liver, with rare reports of severe hepatic necrosis and restrictions for patients with pre-existing hepatic impairment.

Q: What information is available about Eucol causing changes in mood or behavior?

A: Official summaries of adverse reactions have noted anxiety as an incidence-unknown side effect for some patients. Reporting any observed changes in mood or behavior during treatment to a healthcare provider is a standard step.

Q: Does the efficacy of Eucol depend on the patient's age or gender?

A: Pharmacokinetic research indicates that a patient's age and gender can independently influence how the body processes and eliminates Eucol. This means these factors can affect the drug's clearance rate from the body.

Q: What are the official recommendations for stopping Eucol after prolonged use?

A: Official labeling dictates that the course of treatment must be managed by a healthcare provider. Treatment may be interrupted, the dose may be reduced, or the treatment may be stopped entirely, based on the patient's response to the drug and the severity of any side effects experienced.

The official requirements for storing and disposing of Eucol (Paclitaxel concentrate) are strictly defined by regulatory authorities to maintain its stability and manage its status as a cytotoxic agent.

Storage Requirements

Requirement	Official Statement
Temperature & Protection	Store the unopened vial at room temperature (e.g., below 25 C/ 77 F) in the original carton to protect from light.
Prohibited Conditions	Do not refrigerate or freeze the concentrate; precipitation may occur, which must redissolve upon warming or the vial should be discarded.
Container Rule	Preparation and administration must use non-PVC materials (glass, polypropylene, or polyolefin) to avoid plasticizer leaching.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Unused Eucol and all associated waste must be managed according to special procedures. As the medicine is classified as cytotoxic (hazardous) waste, it must not be disposed of via regular household trash or wastewater. All waste materials, including used vials and administration sets, must be collected and disposed of in accordance with local regulations for hazardous medicinal products.